Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible Staphylococcus aureus bacteremia.

Jay Olivet, Matthew L Brown, Megan Amerson-Brown, W Seth Edwards, Robert A Oster, Joshua Stripling
{"title":"Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia.","authors":"Jay Olivet, Matthew L Brown, Megan Amerson-Brown, W Seth Edwards, Robert A Oster, Joshua Stripling","doi":"10.1017/ash.2026.10749","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rapid molecular blood culture identification (BCID) enables earlier pathogen identification and targeted antibiotic therapy compared with traditional culture-based methods. Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) bacteremia is optimally treated with anti-staphylococcal β-lactam antibiotics; however, delays in bacterial identification frequently result in prolonged empiric anti-methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) therapy. Data evaluating the clinical impact of early MSSA identification remain limited.</p><p><strong>Methods: </strong>This retrospective, single-center, quasi-experimental program evaluation included adult patients with monomicrobial MSSA bacteremia. Patients were grouped based on identification by BCID or conventional culture-based methods. Automatic Infectious Diseases consultation was performed for all patients. The primary outcome was a desirability of outcome ranking incorporating treatment success, acute kidney injury (AKI), and inpatient mortality. Secondary outcomes included time-to-optimal therapy, duration of bacteremia, treatment success, and hospital length of stay.</p><p><strong>Results: </strong>A total of 300 patients were included (150 per cohort). BCID use was associated with earlier MSSA identification (0.8 vs 2.1 days; <i>P</i> < .001) and earlier initiation of targeted β-lactam therapy (1.9 vs 3.8 days; <i>P</i> < .001). The probability of a more desirable outcome with BCID was 58.5% (95% CI: 52.5% to 64.3%), and more individuals achieved the most desirable outcome (62.0% vs 46.0%; <i>P</i> = .005). AKI occurred less frequently in the BCID group (23.5% vs 44.2%; <i>P</i> < .001).</p><p><strong>Conclusions: </strong>Incorporation of rapid BCID into an established automatic Infectious Diseases consultation program improved outcomes in MSSA bacteremia by facilitating earlier β-lactam therapy and reducing nephrotoxicity. Antimicrobial stewardship programs should prioritize rapid diagnostics to optimize MSSA management.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"6 1","pages":"e182"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312251/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial stewardship & healthcare epidemiology : ASHE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/ash.2026.10749","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Rapid molecular blood culture identification (BCID) enables earlier pathogen identification and targeted antibiotic therapy compared with traditional culture-based methods. Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is optimally treated with anti-staphylococcal β-lactam antibiotics; however, delays in bacterial identification frequently result in prolonged empiric anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy. Data evaluating the clinical impact of early MSSA identification remain limited.

Methods: This retrospective, single-center, quasi-experimental program evaluation included adult patients with monomicrobial MSSA bacteremia. Patients were grouped based on identification by BCID or conventional culture-based methods. Automatic Infectious Diseases consultation was performed for all patients. The primary outcome was a desirability of outcome ranking incorporating treatment success, acute kidney injury (AKI), and inpatient mortality. Secondary outcomes included time-to-optimal therapy, duration of bacteremia, treatment success, and hospital length of stay.

Results: A total of 300 patients were included (150 per cohort). BCID use was associated with earlier MSSA identification (0.8 vs 2.1 days; P < .001) and earlier initiation of targeted β-lactam therapy (1.9 vs 3.8 days; P < .001). The probability of a more desirable outcome with BCID was 58.5% (95% CI: 52.5% to 64.3%), and more individuals achieved the most desirable outcome (62.0% vs 46.0%; P = .005). AKI occurred less frequently in the BCID group (23.5% vs 44.2%; P < .001).

Conclusions: Incorporation of rapid BCID into an established automatic Infectious Diseases consultation program improved outcomes in MSSA bacteremia by facilitating earlier β-lactam therapy and reducing nephrotoxicity. Antimicrobial stewardship programs should prioritize rapid diagnostics to optimize MSSA management.

快速分子检测对甲氧西林敏感金黄色葡萄球菌菌血症临床结局的影响。
背景:与传统的基于培养的方法相比,快速分子血培养鉴定(BCID)能够更早地识别病原体和靶向抗生素治疗。甲氧西林敏感金黄色葡萄球菌(MSSA)菌血症的最佳治疗方法是抗葡萄球菌β-内酰胺抗生素;然而,细菌鉴定的延误常常导致经验性抗甲氧西林金黄色葡萄球菌(MRSA)治疗的延长。评估早期MSSA识别的临床影响的数据仍然有限。方法:回顾性、单中心、准实验方案评估纳入单微生物MSSA菌血症的成年患者。采用BCID或常规培养方法对患者进行分组。所有患者均进行传染病自动会诊。主要结局是纳入治疗成功、急性肾损伤(AKI)和住院病人死亡率的结局排序的可取性。次要结局包括最佳治疗时间、菌血症持续时间、治疗成功和住院时间。结果:共纳入300例患者(每个队列150例)。BCID的使用与早期发现MSSA (0.8 vs 2.1天,P < 0.001)和早期开始靶向β-内酰胺治疗(1.9 vs 3.8天,P < 0.001)相关。BCID获得更理想结果的概率为58.5% (95% CI: 52.5%至64.3%),获得最理想结果的个体更多(62.0% vs 46.0%; P = 0.005)。BCID组AKI发生率较低(23.5% vs 44.2%; P < 0.001)。结论:将快速BCID纳入已建立的传染病自动会诊计划,通过促进早期β-内酰胺治疗和减少肾毒性,改善了MSSA菌血症的预后。抗菌药物管理计划应优先考虑快速诊断以优化MSSA管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书